NVDA
SLP
Another side quest, but make it pharma
Nvidia has found another place to flex its GPUs: drug development. The company said it’s launching a technical collaboration with Simulations Plus to help speed up computationally heavy modeling and AI-assisted workflows used across the drug development lifecycle.
That’s a fancy way of saying: if the models are too slow, throw more Nvidia horsepower at the problem.
Why this matters
This isn’t just a cute partnership press release. It reinforces Nvidia’s pitch that it’s not only selling the picks and shovels of AI — it’s helping build the whole science lab too.
For investors, the bull case is pretty clear:
- More industries need massive compute
- More compute usually means more Nvidia hardware and software
- More real-world use cases make the AI story feel less like hype and more like infrastructure
The bigger picture
The drug-discovery angle matters because pharma workloads can be expensive, messy, and very compute-hungry. If Nvidia can keep turning “we need faster simulations” into “we need more Nvidia,” that’s the kind of recurring demand Wall Street likes to see.
Big picture: this is another reminder that Nvidia’s growth story isn’t just about chatbots or data centers. It’s about becoming the default engine for anything that needs serious AI muscle.